The prevalence of Lynch syndrome was calculated in a selected high-risk population of colon cancer patients (selected based on meeting one or more Amsterdam and Bethesda criteria) and in high-risk unaffected individuals (based on meeting one or more Bethesda guidelines, having a family history of cancers and/or a known pathogenic variant in MMR gene in the family). The gene discussed is MRC1; the disease is colonic neoplasm.